Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06924307 · ClinicalTrials.gov registry record · NA
Parent-Child EF Intervention
A NA study of Cognitive Intervention to Promote Healthy Development of Executive Function (EF) Skills in Young Children, sponsored by Koronis Biomedical Technologies.
- Recruiting
- Registry status
- NA
- Development phase
- 140
- Enrollment target
- 2
- Study locations
NCT06924307: Recruiting NA study of Cognitive Intervention to Promote Healthy Development of Executive Function (EF) Skills in Young Children, sponsored by Koronis Biomedical Technologies.
NCT06924307 is a NA study of Cognitive Intervention to Promote Healthy Development of Executive Function (EF) Skills in Young Children that is actively recruiting participants, run by Koronis Biomedical Technologies. The registered enrollment target is 140 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06924307, a NA study of Cognitive Intervention to Promote Healthy Development of Executive Function (EF) Skills in Young Children, is actively recruiting participants, sponsored by Koronis Biomedical Technologies.
- RECRUITING
- Registry status
- NA
- Development phase
- 140 participants
- Enrollment target
- 2
- Study locations
Study Summary
Koronis Biomedical Technologies Corporation (KBT) is developing a cognitive intervention to promote healthy development of Executive Function (EF) skills in young children by leveraging a smartphone-based training regime designed for parents.
Primary Outcome
Understanding of EF (From Parent)
Conditions Studied
Interventions
- DEVICE Executive Function Intervention
Study Locations (2)
Minnesota
- University of Minnesota, Institute of Child Development - Minneapolis
New York
- Mount Sinai General Pediatrics - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2026-05-31 |
| Phase | NA |
What NCT06924307 shows while recruiting
NCT06924307 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Cognitive Intervention to Promote Healthy Development of Executive Function (EF) Skills in Young Children appearing as the primary indexed condition, and to 1 intervention - of which Executive Function Intervention is the first listed.
NCT06924307 reports a single indexed study location in Minnesota, New York.
Frequently Asked Questions
What is clinical trial NCT06924307 about?
NCT06924307 is a clinical study titled "Parent-Child EF Intervention". Koronis Biomedical Technologies Corporation (KBT) is developing a cognitive intervention to promote healthy development of Executive Function (EF) skills in young children by leveraging a smartphone-based training regime designed for parents.
What is the current status of trial NCT06924307?
This trial is currently recruiting. It is a NA study. The enrollment target is 140 participants. The study started on 2025-03-10. Estimated completion is 2026-05-31.
What conditions does trial NCT06924307 study?
This clinical trial studies the following conditions: Cognitive Intervention to Promote Healthy Development of Executive Function (EF) Skills in Young Children.
What interventions are being tested in trial NCT06924307?
The interventions under investigation include: Executive Function Intervention (DEVICE).
Who is sponsoring clinical trial NCT06924307?
This trial is sponsored by Koronis Biomedical Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06924307 being conducted?
This trial has 2 study locations across Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06924307's enrollment target sits among peer trials
140 713th of 2000 higher than 1,281 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI